An opinion piece for the Boston Globe points out that public scrutiny and consumer activism is what prompted Johnson & Johnson’s recent decision to phase out questionable chemicals in its full line of products.
The piece applauds that decision, and urges members of the public to keep up that kind of pressure where corporate actions and accountability are concerned.
Johnson & Johnson had already acceded to consumer activists’ demands by saying it ...
continue reading...
The U.S. Food and Drug Administration has agreed to give priority review status to Johnson & Johnson’s application for a new usage of its prostate cancer treatment Zytiga, Reuters reports. That means the drug will be reviewed faster than usual.
The priority review status is granted by the FDA to expedite the review of drugs to treat serious diseases and fill unmet medical needs. It means the drug will be reviewed ...
continue reading...Consumer advocacy group Center for Science in the Public Interest has filed a federal lawsuit over artificial sweetener Splenda Essentials, claiming that Johnson & Johnson subsidiary McNeil Nutritionals is misleading consumers about the product’s supposed health benefits.
In a press release, CSPI says that Splenda Essentials’ marketing is designed to give the false impression that the sweetener confers health benefits, such as helping its users lose weight and avoid disease.
The lawsuit ...
continue reading...
Even as Johnson & Johnson is settling previous charges that may cost about $2.2 billion, the government is making new inquiries into allegations that the company used illegal tactics to promote and market its drugs, the Wall Street Journal reports.
According to the Wall Street Journal, the U.S. Justice Department sent J&J’s Janssen Pharmaceuticals unit a letter in April, requesting documents related to the marketing and promotion of the antibiotic Doribax.
In ...
continue reading...
The investment blog Seeking Alpha says Johnson & Johnson is doing quite well financially despite its recent problems – including high-profile and costly recalls of faulty medical devices.
The report notes that Warren Buffett’s Berkshire Hathaway Inc. dropped two-thirds of its holdings in the company, following a $1.1 billion fine from an Arkansas jury that ruled the firm misled doctors and patients about the risks of antipsychotic medication Risperdal.
Johnson & Johnson ...
continue reading...Johnson & Johnson will pay 36 states and the District of Columbia $181 million as a settlement for allegations that the company inappropriately marketed its antipsychotic drug Risperdal, the Philadelphia Inquirer reports.
Federal and state investigators have been examining the company’s Risperdal marketing practices for almost a decade, according to the Inquirer. The $181 million agreement is separate from a continuing federal investigation that could lead to criminal charges against Johnson ...
continue reading...
